An update in treatment options for multiple myeloma in nontransplant eligible patients

摘要

Introduction: Despite the fact that multiple myeloma (MM) is still an incurable disease, the outcome of patients who are eligible and ineligible for high-dose therapy has dramatically improved with the introduction of novel agents, that is proteasome inhibitors (Pis) and immunomodulatory agents (IMiDs). However, this improvement is often not seen in elderly patients (above 75 years).